HeartBeam (NASDAQ: BEAT) was among the medical device companies highlighted in a Jan. 8 report by Modern Healthcare by Lauren Dubinsky that outlined FDA clearances and approvals across the medical device sector. HeartBeam’s 12-lead electrocardiogram synthesis software was cleared Dec. 8 to assess arrhythmias by converting heart signal data captured from 3 dimensions using the company’s portable, non-invasive recorder into a standard 12-lead ECG format suitable for remote clinical review.
HeartBeam recently reinforced its technology leadership with recognition as a Global IP and Technology Leader in Portable Cardiac Diagnostics, ranking second worldwide and trailing only GE Healthcare, in 12-lead ECG innovation among 243 companies evaluated in PatentVest’s “Total Cardiac Intelligence” report, according to an InvestorBrandNetwork report. The ranking reflects the strength of its intellectual-property foundation, with 82 global patent publications across 15 patent families supporting its three-dimensional cardiac signal capture and 12-lead ECG synthesis architecture, underscoring the company’s growing influence in next-generation remote cardiac monitoring.
To learn more about Heartbeam’s Portable ECG Technology, visit https://nnw.fm/42QRB
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://nnw.fm/BEAT
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer